Clara Cerrato, Fabio Crocerossa, Michele Marchioni, Gianluca Giannarini, Shilpa Gupta, Laurence Albiges, Oscar Brouwer, Maarten Albersen, Christian Fankhauser, Marc Oliver Grimm, Giorgio Gandaglia, Morgan Roupret, Maria Carmen Mir
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) herald a transformative era in metastatic renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) treatment, amid acknowledged sex-based disparities in these cancers. We conducted a systematic review and network meta-analysis (NMA) to identify sex-specific differences in the efficacy of ICI/ADC monotherapy or combination therapies for RCC and TCC survival, in metastatic and adjuvant settings...
April 20, 2024: European Urology Oncology